Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.1% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 0.1% during trading on Wednesday . The company traded as low as $6.65 and last traded at $6.76. Approximately 12,067,375 shares were traded during mid-day trading, an increase of 74% from the average daily volume of 6,933,797 shares. The stock had previously closed at $6.77.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Trading Up 6.7 %

The company has a market capitalization of $2.82 billion, a PE ratio of -4.71 and a beta of 0.85. The company has a fifty day simple moving average of $6.84 and a 200-day simple moving average of $7.09. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the company posted ($0.43) EPS. The company’s revenue for the quarter was up 147.6% compared to the same quarter last year. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In other news, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total value of $94,800.00. Following the transaction, the chief financial officer now directly owns 1,426,506 shares in the company, valued at approximately $9,015,517.92. This represents a 1.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,288,380.78. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 70,341 shares of company stock valued at $488,290. 15.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in Recursion Pharmaceuticals by 20.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,060,804 shares of the company’s stock valued at $7,956,000 after acquiring an additional 178,994 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Recursion Pharmaceuticals by 39.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 49,863 shares of the company’s stock valued at $374,000 after purchasing an additional 14,060 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in Recursion Pharmaceuticals by 25.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company’s stock worth $332,000 after buying an additional 9,058 shares during the period. Rhumbline Advisers lifted its holdings in Recursion Pharmaceuticals by 24.1% during the 2nd quarter. Rhumbline Advisers now owns 281,348 shares of the company’s stock worth $2,110,000 after buying an additional 54,576 shares in the last quarter. Finally, Foundations Investment Advisors LLC boosted its position in Recursion Pharmaceuticals by 296.1% in the 2nd quarter. Foundations Investment Advisors LLC now owns 154,394 shares of the company’s stock valued at $1,158,000 after buying an additional 115,418 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.